William R. Miller
Edinburgh, SCT EH42XU, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Journal: The Journal of steroid biochemistry and molecular biology
Published: February 09, 2016
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
Journal: Breast cancer research : BCR
Published: April 15, 2014
Trends in the distribution of breast cancer over time in the southeast of Scotland and review of the literature.
Journal: Ecancermedicalscience
Published: October 06, 2013
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Journal: Breast cancer research : BCR
Published: August 08, 2013
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 16, 2013
Understanding the mechanisms of aromatase inhibitor resistance.
Journal: Breast cancer research : BCR
Published: January 27, 2012
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Journal: Cancer discovery
Published: November 04, 2011
Bridging the gap between translational research and clinical application.
Journal: Journal of the National Cancer Institute. Monographs
Published: November 02, 2011
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).
Journal: Journal of the National Cancer Institute. Monographs
Published: November 02, 2011
Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients.
Journal: The Journal of steroid biochemistry and molecular biology
Published: October 23, 2011
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Journal: Endocrine-related cancer
Published: October 11, 2011
Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer.
Journal: Expert review of endocrinology & metabolism
Published: May 01, 2011
Last Updated: 09/26/2026